A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (CARTITUDE-6)
A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible
Sponsor: Janssen Research & Development, LLC
This PHASE3 trial investigates Multiple Myeloma and is currently ongoing. Janssen Research & Development, LLC leads this study, which shows 20 recorded versions since 2023 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
20 versions recorded-
Jan 2026 — Present [monthly]
Active Not Recruiting PHASE3
-
Oct 2025 — Jan 2026 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE3
-
Jun 2025 — Sep 2025 [monthly]
Recruiting PHASE3
-
Feb 2025 — Jun 2025 [monthly]
Recruiting PHASE3
▶ Show 15 earlier versions
-
Dec 2024 — Feb 2025 [monthly]
Recruiting PHASE3
-
Nov 2024 — Dec 2024 [monthly]
Recruiting PHASE3
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE3
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE3
-
Apr 2024 — Jun 2024 [monthly]
Recruiting PHASE3
-
Feb 2024 — Apr 2024 [monthly]
Recruiting PHASE3
-
Jan 2024 — Feb 2024 [monthly]
Recruiting PHASE3
-
Dec 2023 — Jan 2024 [monthly]
Recruiting PHASE3
-
Nov 2023 — Dec 2023 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Sep 2023 — Nov 2023 [monthly]
Not Yet Recruiting PHASE3
-
Apr 2023 — Sep 2023 [monthly]
Not Yet Recruiting PHASE3
-
Sep 2022 — Apr 2023 [monthly]
Not Yet Recruiting PHASE3
-
Mar 2022 — Sep 2022 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Janssen Research & Development, LLC
- Stichting European Myeloma Network
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amsterdam, Netherlands , Anderlecht, Belgium , Antwerp, Belgium , Athens, Greece , Atlanta, United States , Badalona, Spain , Baltimore, United States , Barcelona, Spain , Basel, Switzerland , Bern, Switzerland and 86 more locations